ABSTRACT
Zidovudine administration either in single or fixed-dose combination usually results in a decrease in body weight and in some cases thrombocytopenia. The present study investigated the body weight and platelet count changes observed in zidovudine pre-administered Wistar albino rats on treatment with ethanolic extracts of the leaves Annona muricata (AM) and roots of Fagara zanthoxyloide (FZ). Plants samples were collected from Alakahia community, Rivers state and Opoo community, Ogun state; while Wistar albino rats were grouped into normal control, negative control (receiving zidovudine at 100 g/ml/Kg bw), AM and FZ extract treatment (at 4.5 and 3.8 g/ml/Kg B.W respectively) groups with analysis performed bi-weekly. All tests were performed using standard procedures with all reagents of analytic grade. Phytochemical screening of the extracts showed significantly high amounts of alkaloids (10.47- 21.15 mg / 100 g), phenols (10.60-15.22 mg / 100 g) and tannins (14.23 - 50.19 mg / 100 g). The investigation into their proximate compositions also showed high fat (5.78 ± 0.02) in FZ, moisture (10.47 ± 0.05) in AM and fibre (7.37 ± 0.03) in FZ. The amino acid phenylalanine (5.10-6.01 g / 100 g), isoleucine (4.44-5.20 g / 100 g), lysine (4.03 -5.31 g / 100 g) was observed to be available in the extracts. In the normal control group body weight increased by 20.75 g at week 6 while administration of Zidovudine, resulted in a decreased in bodyweight by 1.14 g in week 2 and 3.32 g in week 6. Extract treatment caused a significant increase (p?0.05) in body weight by 17.95g (AM) and 18.23g (FZ) at week 6. Platelet count was also observed to significantly decrease (p?0.05) by 33.42% in the negative control group when compared to the normal control. This was observed to significant increases in extract treatment by 49.56% (AM) and 51.32% (FZ). The results thus suggest a possible beneficial effect of the extracts of AM and FZ in checkmating the weight and platelet loss observed as a side effect of zidovudine therapy as well as the possible use in haemorrhagic conditions to reduce bleeding without thromboembolism.
ABSTRACT
Background: Blood coagulation abnormalities are common in persons infected with the human immunodeficiency virus (HIV). However, few studies showed the association of these abnormalities with anti-retroviral therapy (ART). Objective: This cross-sectional study investigated the effects of ART on blood coagulation parameters of patients infected with HIV attending HIV special clinics of the University of Abuja Teaching Hospital (UATH), Gwagwalada, Abuja, Nigeria. Material and Methods: A total of 191 patients comprising 128 HIV subjects on ART (test subjects) and 63 other HIV patients not on ART (control subjects) were included in the study. CD4+ lymphocyte counts, platelet counts, prothrombin time (PT) and partial thromboplastin time with kaolin (PTTK) of subjects were determined using flow cytometry, automated hematology analyser and Quick one-stage methods respectively. Results: Of the total test subjects, 21 (16.4%) were CD4 lymphopaenic, and the mean CD4+ cell count for the test subjects was statistically higher than that of the control subjects (578 versus 322 cells/ mm3 ) (p = 0.014). Eight (6.3%) of test subjects had prolong PTTK, and the mean values of PT and PTTK were statistically not significant between test subjects and control subjects (p = 0.358 and p= 0.141 respectively). Eight (6.3%) of test subjects had thrombocytopaenia, the mean platelet count was significantly lower than that of the control subjects (238 versus 278.6 x 109 /L, p = 0.001), and also varied significantly with the duration of ART (p = 0.0086). Conclusion: Findings from this study revealed ART decreased platelet counts of HIV-infected individuals, but did not affect the PT and PTTK results.
ABSTRACT
Objective To explore the application of evaluation of measurement uncertainty in routine coagulation assays based on the data of internal quality control (IQC) and results of external quality assessment (EQA) .Methods Data of clinical coagulation assays of clinical laboratory of Xiangyang city hospital were collected ,Which came from six months of IQC and 3 times of EQA of ministry of health clinical laboratory center from 2012 to 2013 .The combined and expanded uncertainties of 3 measurements(PT , APTT and Fbg) were evaluated according to CNAS top-downapproach .Results When PT were in 12 .72 s and 21 .04 s ,its ex-panded uncertainty were 1 .06 s and 1 .96 s ,and APTT in 36 .6 s and 50 .6 s were 2 .59 s and 5 .30 s ,and Fbg in 3 .32 g/L was 0 .30 g/L .Conclusion Evaluation of measurement uncertainty by using internal quality control data and EQA results for routine coagula-tion detection index is economical and practical and acceptable way ,with good clinical practice .
ABSTRACT
BACKGROUND Coagulation assays can be easily affected by preanalytical variables, including the factors associated with the blood collection tube. Recently the Sekisui Trank Insepack (Sekisui Chemical Co., Ltd, Osaka, Japan; Insepack) blood collection tubes were introduced into Korea. The aim of this study was to compare the results of routine coagulation assays using the Insepack with those using BD Vacutainer (BD, Franklin Lakes, NJ, USA; Vacutainer) tubes, which are most widely used in Korea. METHODS: Paired blood samples from 64 patients were drawn into Insepack and Vacutainer 3.2% citrate tubes. The results of prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen, and fibrin/fibrinogen degradation product (FDP) were determined in parallel. RESULTS: No statistically significant differences were observed between Insepack and Vacutainer tubes for PT, fibrinogen, and FDP tests. For APTT which showed the significant differences between the results in the two tubes the mean difference was small (0.8 seconds), and it was not considered clinically significant. CONCLUSIONS: The results of this study suggest that Insepack tubes can be used in place of Vacutainer tubes for routine coagulation assays.